Kidney cancer news
ESMO 2023: Does stopping VEGFR TKI treatment and continuing immunotherapy influence the survival of patients on combination therapy?
In many countries, combinations of VEGFR TKI anti-cancer mediations plus [...]
ESMO 2023: A new immunotherapy, volrustomig, for the first-line treatment of advanced kidney cancer
Blocking the action of two proteins in cancer cells (PD-1 [...]
ESMO 2023: A new first-line treatment, toripalimab, for advanced kidney cancer
Advanced/metastatic kidney cancer is often treated with a combination of [...]
ESMO 2023: Belzutifan for the treatment of advanced kidney cancer
Treatments for people with metastatic kidney cancer have changed over [...]
Action Kidney Cancer at the ESMO Congress
Steve Pointon, person centred counsellor kidney cancer patient and one of [...]
Patients with metastatic kidney cancer on immunotherapy may benefit from nephrectomy
Surgery to remove the kidney and tumour (nephrectomy) has an [...]
Most used tags
renal cell carcinoma immunotherapy combination therapy checkpoint inhibitors Cancer nivolumab TKIs overall survival Opdivo sunitinib Sutent cabozantinib progression-free survival NHS England biomarkers ipilimumab Cabometyx pembrolizumab COVID-19 axitinib cancer survival non-clear cell kidney cancer VEGF inhibitors Inlyta coronavirus Yervoy risk factors Keytruda metastases adjuvant therapy targeted therapy biological markers papillary RCC everolimus kidney cancer Afinitor cancer outcomes first-line treatment ASCO NICEArchives
- 2023: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2022: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2021: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2020: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2019: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2017: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2016: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
